Klin Onkol 2015; 28(Suppl 4): 69-72. DOI: 10.14735/amko20154S69.
Summary In recent years, thanks to new advances in tumor immunology, immunotherapy became a part of intensive research as a novel strategy in cancer treatment. Sipuleucel- T is the first and only medicinal product approved by the regulatory agencies in the USA and Europe for the treatment of asymp tomatic or minimal symp tomatic castrate- refractory prostate cancer. It represents the first product of autologous cell therapy. This article gives a brief overview of new approaches in cancer immunotherapy in clinical development.
